Publications by authors named "Jon Kerry"

Claim this Profile
B
BET inhibition disrupts transcription but retains enhancer-promoter contact.
Nicholas T Crump, Erica Ballabio, Laura Godfrey, Ross Thorne, Emmanouela Repapi, Jon Kerry

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-resolution targeted 3C interrogation of cis-regulatory element organization at genome-wide scale.
Damien J Downes, Robert A Beagrie, Matthew E Gosden, Jelena Telenius, Stephanie J Carpenter, Jon Kerry

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of the 4D genome during in vivo lineage specification and differentiation.
A Marieke Oudelaar, Robert A Beagrie, Matthew Gosden, Sara de Ornellas, Emily Georgiades, Jon Kerry

Nat Commun· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia.
Akihiko Numata, Hui Si Kwok, Akira Kawasaki, Jia Li, Qi-Ling Zhou, Jon Kerry

Nat Commun· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.
Sachith Mettananda, Chris A Fisher, Deborah Hay, Mohsin Badat, Lynn Quek, Jon Kerry

Nat Commun· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats.
Diu Tt Nguyen, Hsiao Phin J Voon, Barbara Xella, Caroline Scott, David Clynes, Jon Kerry

EMBO Rep· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.
Laura Godfrey, Jon Kerry, Ross Thorne, Emmanouela Repapi, James O J Davies

Exp Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Jon Kerry, Laura Godfrey, Emmanouela Repapi, Marta Tapia, Neil P Blackledge

Cell Rep· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.
Shan Lin, Roger T Luo, Anetta Ptasinska, Jon Kerry, Salam A Assi

Cancer Cell· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
Juliana M Benito, Laura Godfrey, Kensuke Kojima, Leah Hogdal, Mark Wunderlich, Jon Kerry

Cell Rep· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.
Adam C Wilkinson, Erica Ballabio, Huimin Geng, Phillip North, Marta Tapia, Jon Kerry

Cell Rep· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis